https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-14 / PLoS ONE 2014;9(8):e105266
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-14 / PLoS ONE 2014;9(8):e1052662014-08-14 00:00:002019-02-15 08:48:44Efficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-12 / Front Oncol 2014;4:217
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-12 / Front Oncol 2014;4:2172014-08-12 00:00:002019-02-15 09:22:37Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-05 / Int. J. Cancer 2015 Feb;136(4):E74-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-05 / Int. J. Cancer 2015 Feb;136(4):E74-842014-08-05 00:00:002019-02-15 08:46:15Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-01 / Int J Hyperthermia 2014 Aug;30(5):285-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-01 / Int J Hyperthermia 2014 Aug;30(5):285-942014-08-01 00:00:002014-08-01 00:00:00Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-31 / J Clin Oncol 32, 2014 (suppl 3; abstr 69)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-31 / J Clin Oncol 32, 2014 (suppl 3; abstr 69)2014-07-31 12:08:122019-09-30 09:32:18The effect of stress on efficacy of dendritic cell therapy for esophageal squamous cell carcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-31 / J Clin Oncol 32, 2014 (suppl 4; abstr 189)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-31 / J Clin Oncol 32, 2014 (suppl 4; abstr 189)2014-07-31 12:07:522019-09-30 11:21:53Response of blood flow to hyperthermia in human prostate tumors: Opportunities for enhanced radiation effect and drug delivery.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-31 / J Clin Oncol 32, 2014 (suppl 4; abstr 490)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-31 / J Clin Oncol 32, 2014 (suppl 4; abstr 490)2014-07-31 11:52:432021-08-09 07:54:15A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-30 / BMC Cancer 2014 Jul;14:551
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-30 / BMC Cancer 2014 Jul;14:5512014-07-30 00:00:002014-07-30 00:00:00Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-24 / Oncol Lett 2014 Oct;8(4):1783-1787
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-24 / Oncol Lett 2014 Oct;8(4):1783-17872014-07-24 00:00:002019-04-03 11:16:21Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-22 / J Transl Med 2014 Jul;12:209
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-22 / J Transl Med 2014 Jul;12:2092014-07-22 00:00:002019-02-15 08:48:43Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised „proof-of-principle“ phase II study
